Introduction
Angiotensin converting enzyme inhibitors improve symptoms and reduce mortality in congestive heart failure 1 ' 21 . However, in clinical practice, many heart failure patients take doses of angiotensin converting enzyme inhibitors that are far below the doses that have been used in the studies that conclusively showed the symptomatic and prognostic benefits of these drugs.
There are few studies showing clinical benefit with low doses of angiotensin converting enzyme inhibitors and few studies comparing the effects of low versus high doses of angiotensin converting enzyme inhibitors in heart failure 131 . A dose-response relationship was found in a dose ranging study with quinapril in doses ranging from 5 to 20 mg twice daily, patients receiving higher doses having greater increments in exercise performance 14 '. In contrast, no dose-dependent increase in exercise tolerance was detected with cilacapri! in doses ranging from 0-5 to 2-5 mg daily in one study* 51 , whereas in another study with higher cilacapril dosages exercise variables were found to be improved' 61 . The only randomized dose ranging study so far reported with enalapril included only 27 patients, but the results showed that patients treated with enalapril 15 mg twice daily were less likely to deteriorate than patients treated with 2-5 mg twice daily 171 . An interesting observation with regard to the prognostic impact of short versus long-acting angiotensin converting enzyme inhibitors was made in a trial of xamoterol in severe heart failure 181 . Xamoterol increased mortality, but in retrospect, patients on captopril had a higher mortality than those on concomitant enalapril treatment. We observed in a previous study, when we compared more or less than 25 mg three times daily captopril for the treatment of severe heart failure, that patients taking higher doses had a greater improvement in symptoms and were more likely to have a reduction in aldosterone and atrial natriuretic peptide plasma levels after 6 months 19 '. They were also less likely to undergo transplantation or die. However, since our study was not randomized we could not rule out the potential selection bias that the ability to tolerate high doses of captopril as such may have indicated a better prognosis.
Thus, questions remain concerning the effect of low versus high angiotensin converting enzyme inhibitor dosages in heart failure, particularly in the long term and at an advanced stage of the disease. In this doubleblind prospective study the primary endpoint was whether an increase in dose of a long-acting angiotensin converting enzyme inhibitor, enalapril, would result in a greater improvement in clinical symptoms than a low, more widely used dose. In addition, effects of both treatments on haemodynamics at rest, on maximal exercise capacity, and on the activity of neurohumoral systems were evaluated.
Methods

Study design and patient definition
This was a 48 week, double-blind, randomized, controlled, parallel, monocentric study of 83 patients with severe congestive heart failure in New York Heart Association functional class III-IV while receiving digitalis, diuretics and low dose angiotensin converting enzyme inhibitor therapy (enalapril <, 10 mg . day" ' or captopril ^50 mg. day" ') for at least 3 months before entry. In 22 patients aspirin (100 mg . day" ') was used to inhibit platelet aggregation.
The clinical diagnosis of congestive heart failure was confirmed by at least one of the following parameters: an elevated right atrial mean pressure (>10mmHg) or pulmonary artery mean pressure (>35 mmHg) or reduced cardiac index (<2-5 1. min" ' . m"
2 ) upon initial haemodynamic evaluation which was performed after a run-in stabilization period of at least 2 weeks, when previous angiotensin converting enzyme inhibitor regimens were withdrawn and patients received enalapril 5 mg b.i.d. in an open fashion. Patients who needed treatment with beta-blockers or calcium channel antagonists were not included. Dose of digoxin and diuretics were continued at a constant dose.
Exclusion criteria included an age of >70 years, a history of enalapril intolerance, haemodynamically serious valvular disease requiring surgery, recent unstable angina, myocardial infarction or cerebrovascular accident (during the previous month), severe pulmonary disease, clinically important renal, hepatic or haematological disorders, hyperkalaemia, hypokalaemia or serum creatinine level >2 mg. 100ml"' or any other disease that might substantially shorten survival or impede participation in a long-term trial.
Drug administration and monitoring
Patients were randomized according to a computergenerated allocation schedule. Adherence to random assignment was confirmed by Merck Sharp and Dohme Ltd., which held the only master code. Patients who were allocated to the low-dose group were treated with a daily dosage of 10 mg (5 mg b.i.d.) enalapril and placebo throughout. Patients who were assigned to the high-dose group were started at 5 mg twice daily and titrated up to 40 mg per day of enalapril, in two daily intakes. Patients were seen at weekly intervals until a maximum study dose was reached after 4 weeks and then after 12, 24 and 48 weeks. All patients tolerated the dose titration without a decrease in systolic blood pressure below 90 mmHg. In patients with worsening symptoms of congestive heart failure during the study, an increase in the dose of diuretic agents or nitrates was generally recommended as the first step. If, however, clinical signs of overt heart failure occurred despite maximal therapy, the blinded medication was discontinued.
The protocol was approved by the local institutional ethical committee and all patients had given written consent.
Evaluation criteria
The patient's clinical condition (vital signs and clinical signs) was assessed and physical examination including systolic and diastolic blood pressure was performed at each clinical visit. Haemodynamic and laboratory tests were performed at selected time points, as given in the flow chart (Fig. 1) .
Haemodynamic measurements
Right heart catheterization was performed at rest and during exercise on a supine bicycle with stepwise increases in workload (25 W at 2 min intervals) using a thermodilution, four-channel Swan-Ganz flow-directed balloon-tipped catheter (Edwards Laboratories, Anasco, Puerto Rico, Model 93A -931 H/7.5 F) connected to a Gould-Statham P23D pressure transducer (Gould Inc., Cleveland, Ohio). Cardiac output was calculated with a thermodilution computer (Baxter-Edwards, REF. obtain heart rate. Arterial blood pressure was measured by cuff. Haemodynamic indices were calculated according to standard formulae.
Laboratory measurements
Venous blood samples were drawn from indwelling catheters after a 30 min supine rest for determination of noradrenaline (by high pressure liquid chromatography), renin activity (radioimmunoassay), aldosterone (radioimmunoassay), atrial natriuretic peptide (radioimmunoassay) and big endothelin-1, which is a major component of total immunoreactive endothelin-1 in plasma of heart failure patients' 101 . For determination of big-endothelin, C-terminal big-endothelin-1 was measured by an extraction based radioimmunoassay, as described in detail elsewhere 1111 .
Statistical methods
Continuous variables are expressed as means ± SEM. Patient characteristics were compared using the Fisher's exact test for dichotomous variables or the Wilcoxon rank-sum test for ordered categorical data. The comparability of the treatment groups at baseline was assessed by the McCullagh's method with treatment as factor for the New York Heart Association score, by ANOVA with treatment as factor effect for diastolic and systolic blood pressure and right heart catheterization, and by means of ANOVA on the ranked values with treatment as factor for neurohumoral activity.
The efficacy analyses were performed using an 'intention to treat' approach; that is, all patients with efficacy data both at baseline and on treatment were analysed including protocol violators or drop-outs. If in the 'intention to treat' approach a patient's data were missing at weeks 24 or 48, the last observation prior to that week was carried forward and used in the analyses. Patients who died during the study or within 14 days after the end of the study for a reason other than congestive heart failure worsening, were assigned the New York Heart Association score of their previous visit while patients who died because of congestive heart failure worsening were put in the worst category. Patients who underwent heart transplantation were given the score of their previous visit since they were already a candidate for heart transplant at the start of the study. The comparison between the two groups was made using McCullagh's method (for ordered categorical variables) with baseline and treatment as model effects and with ANOVA on the ranks with treatment as model effect.
Within group comparisons, to assess the significance of the change from baseline in the two treatment groups separately, were made using the Wilcoxon signed-rank test and paired t-test. Efficacy ordered categorical variables were analysed by McCullagh's method. Treatment groups were compared with regard to the incidence of clinical and laboratory adverse effects by means of Fisher's exact test. Kaplan Meier survival estimates and the log-rank test were used to compare survival between groups. A / > <005 was considered significant in all analyses. Table 1 summarizes demographic and clinical characteristics of 83 patients who entered the run-in stabilization period. Forty-two were randomized to the low-dose group and 41 patients to the high-dose group. The treatment groups were similar with respect to key demographic and clinical signs of congestive heart failure as well as concerning concomitant treatments with digitalis, diuretics, nitrates and aspirin, but there was a significant difference between the two groups with respect to aetiology of congestive heart failure (P=004).
Results
Patient characteristics and comparability
Functional assessments (New York Heart
Association class)
Due to two drop-outs, as shown in Fig. 2 , the low-dose group comprised 41 patients and the high-dose group (21) 24 (57) 27 (64) 14 (24) 20 (48) 1 (2) 0 6(14) 9 (21) 42 (100) 42 (100) 21 (50) 10 (24) 81 ± 13
1 (2) 6 (14) High dose (n=41) (61) 29 (71) 11 (27) 26 (63) 1 (2) 1 (2) 9 (22) 11 (27) 41 (100) 41 (100) 30 (73) 12 (29) 90± 13 1 (2) 10 (24) ACE, angiotensin converting enzyme; AICD, automatic implanted cardiac defibnllator; NYHA, New York Heart Association. Data are mean ± SEM or numbers (%). 'Significant difference (/ > =004) between the two groups with respect to aetiology; more patients in the low-dose group had idiopathic cardiomyopathy and more patients in the high-dose group had ischaemic heart disease. No other significant differences between groups comprised 40 patients for analysis of New York Heart Association class. Both groups were comparable with regard to New York Heart Association score at baseline. At weeks 12, 24 and 48, NYHA class decreased from baseline in the low-dose group as well as in the high-dose group, but the magnitude of change from baseline was not different between the groups at weeks 12 and 24. At week 48, however, the improvement in New York Heart Association class was larger (-0-9) in the high-dose group than in the low-dose group (-0-5), resulting in a significantly different change (P=004) between both treatments (Fig. 3) .
As a consequence, at week 48, the proportion of patients with New York Heart Association class III-IV was higher in the low-dose group (54%) than in the high-dose group (35%) (P-00\). 
Systolic and diastolic blood pressure
Both groups were comparable with regard to systolic and diastolic blood pressure at baseline (Table 2) . At weeks 12 and 24 systolic blood pressure decreased and the changes from baseline were significantly more pronounced in the high-dose group than in the low-dose group (/ > =001 and / > =005, respectively). At week 48, however, changes in systolic blood pressure from baseline were no longer different between the treatments. Diastolic blood pressure decreased at weeks 12, 24 and 48 and the magnitude of change from baseline was significantly different between both treatments at all weeks (P-00\) (Fig. 4) .
Haemodynamic results
Baseline right heart catheterization was performed in 41 of 42 patients in the low-dose group and in all 41 patients in the high-dose group. In one patient right heart catheterization was technically impossible. There was no significant difference in haemodynamic variables at rest between the treatment groups ( Table 2 ). Due to 23 drop-outs, as shown in Fig. 2 , a second haemodynamic test was performed in 29 patients on the low dose and in 31 patients on the high dose at week 24. In addition, at week 48 haemodynamic data are missing in four of 19 study-completing patients on the low dose and in one of 24 study-completing patients on the high-dose because of technical problems. Baseline haemodynamic variables at rest were comparable in the two subsets with sequential haemodynamic data and changes in haemodynamic variables from baseline at weeks 24 and 48 were not significantly different between either treatment. Pulmonary capillary wedge pressure, however, showed a tendency to a more pronounced decrease on the high dose (P-006) ( Table 3 ). 
Exercise capacity
In 41 of 42 patients in the low-dose group and in 39 of 41 patients in the high-dose group maximal exercise capacity was established. In two patients in the highdose group exercising was technically impossible. There was no difference in exercise capacity at baseline between either treatment group (Table 2) . Due to 23 drop-outs, as shown in Fig. 2 , a second exercise test was performed in 29 patients on the low dose and in 31 patients on the high dose at week 24. In addition, at week 48 exercise data are missing in four of 19 studycompleting patients on the low dose because of technical problems. Baseline exercise variables were comparable in the two subsets with sequential exercise data and changes from baseline in exercise variables, including mean pulmonary artery pressure, were not significantly different between either treatment at weeks 24 and 48. At week 48, maximal workload and respective exercise time showed a tendency to a more pronounced increase on high dose (/ ) =008 and P=007 between both treatments) ( Table 4) . 
Plasma renin activity and aldosterone
At week 12, there was a significant difference the low-and high-dose groups i change from baseline in plasma However, at weeks 24 and 48, ivith respect to Data are group and between the mean renin activity (P-0-04). both treatment groups were again comparable with respect to the magnitude of change in plasma renin activity evels from baseline. The fSignificance of between-group changes. Abbreviations: HR, heart rate; MAP, mean arterial pressure; RAP, right atrial pressure; PAP, pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; SVI, stroke volume index; CI, cardiac index; SVRI, systemic vascular resistance index; PVRI, pulmonary vascular resistance index. Data are mean ± SEM; */><005, ••/><001 vs baseline within the low-dose group and within the high-dose group.
Neurohumoral plasma levels
Analyses were performed at weeks 12, 24 and 48 for: plasma aldosterone, plasma renin activity and plasma atrial natnuretic peptide in 39 patients in the low-dose group and in 35 patients in the high-dose group; plasma noradrenaline in 37 patients in the low-dose group and in 34 patients in the high-dose group; and plasma big endothelin in 38 patients in the low-dose group and in 34 patients in the high-dose group. There was no significant difference in any of the measured neurohumoral plasma levels between the two treatment groups at baseline (Table 5) . treatment groups were similar with respect to the mean change from baseline in aldosterone plasma levels at all weeks.
Noradrenaline
There was no significant difference with respect to the mean change from baseline in plasma noradrenaline between the treatment groups at weeks 12 and 24. At week 48, however, there was a tendency to a difference with respect to the mean change from baseline in plasma noradrenaline between the low-and high-dose group (P=009).
Big endothelin and atrial natriuretic peptide
The treatment groups were similar with respect to the mean change from baseline in big endothelin and atrial natriuretic plasma levels at all weeks.
Changes in kidney function
There were small, but significant increases in the plasma levels of creatinine in the low-dose group and in the high-dose group at week 48 ( Table 6 ). The changes in plasma creatinine levels were, however, similar on both treatments. The proportions of patients with changes outside predefined limits of an increase more than 0-2 mg creatinine . dl ~' from baseline were not signifiNon-compliance 8 (19%) 4 (9-8%) Protocol violation 1 (2-3%) 2 (4 8%) Adverse clinical experience* 1 (2-3%) 1 (2-4%) Worsening of CHF 3(71%) 3(7-3%) Heart transplantation 3(7-1%) 2(4-8%) Death 7 (17%) 5 (12%) Total drop-outs 23 (55%) 17 (41%) CHF, congestive heart failure. Numbers represent patients and percentages of drop-outs in the group, respectively. 'Surgery (femoral artery occlusion) in one patient in the low-dose group; coma in one patient in the high-dose group; no significant differences between groups.
cantly different between the two treatment groups (20% in the low-dose group versus 25% in the high-dose group). The plasma levels of potassium did not change on average. The proportions of patients with changes outside predefined limits of a decrease or an increase of more than 0-5mmol.l~' in plasma potassium from baseline were not different between the two treatment groups (3% in the low-dose group versus 0% in the high-dose group or 5% in the low-dose group versus 6% in the high-dose group, respectively).
Discontinuation of treatment
The study was completed by 19 of 42 (45%) patients in the low-dose group and by 24 of 41 (58%) patients in the high-dose group, as shown in Fig. 2 . Reasons for discontinuation of treatment are summarized in Table 7 .
A total of 41 patients had at least one clinical adverse experience (death and heart transplant included) during the active treatment phase, 24 patients (57%) in the low-dose group and 17 patients (42%) in the high-dose group. No patients were withdrawn from therapy because of laboratory adverse experiences. The proportion of patients with adverse experiences was similar in both treatment groups (Table 8) .
Clinical outcome
The cause of a patient's death was classified on the basis of the blinded review of the circumstances surrounding the death, as obtained from the hospital chart or from interviews with relatives. Fifteen patients (18-5%) died during or within 2 weeks after therapy, eight patients in the low-dose group and seven patients in the high-dose group. There was no significant difference between the treatment groups with respect to number of deaths ( Table 9) .
Effect of aspirin
Patients were also analysed according to the use of anti-thrombotic therapy with aspirin at a daily dose (5) 0 CHF, congestive heart failure; Ml, myocardial infarction, PM, pacemaker; CV, cardiovascular Numbers represent patients and percentages of adverse experiences in the group, respectively No significant differences between groups. of 100 mg. Distribution of New York Heart Association class, blood pressure or exercise capacity were not influenced whether patients took aspirin or not, neither in the study patients as a whole nor within the low-dose group or within the high-dose group. Moreover, outcome distribution (survivors, transplanted patients, deaths and drop-outs) in patients on concomitant aspirin was not different from that in patients without aspirin.
Discussion
Impact of low versus high enalapril on symptoms and exercise tolerance
In this randomized double-blind comparison of two different enalapril dosages, a population of severe heart failure patients had a significantly greater symptomatic benefit after 1 year if patients were uptitrated from a previously low enalapril dose (10 mg . day ~ ') to a high enalapril dose (40 mg . day" '). Concerning safety with high enalapril dose, it was as well tolerated as the low dose and similar numbers of patients dropped out or had to be discontinued from double-blind treatment because of clinical adverse events in the high-dose group as in the low-dose group. Thus, no clinical adverse events could be attributed to high enalapril dosages as such.
The clinical improvement on high versus low enalapril dose was mirrored by a marginal increase in exercise capacity, although statistical significance was not reached between the treatments. On first glance, this failure to produce a more pronounced effect on exercise tolerance may appear an unexpected result, because in a previous dose ranging study with quinapril, higher doses were clearly shown to produce a more pronounced improvement in exercise capacity than lower doses' 4 '. On the other hand, with cilacapril no dose-response relationship could be shown in one study* 51 , while in another study cilacapril was quite effective in improving exercise capacity when given at a higher, probably more adequate dose' 6 '. There are, however, several differences besides the chosen angiotensin converting enzyme inhibitors between these trials and our study concerning severity of heart failure, duration of treatment and study design. In our study it was provided that patients who were allocated to receive a 1-year low-dose treatment had actually no change in enalapril dose after randomization.
Evaluation of neurohumoral systems
As assessed by blood pressure measurements, the higher enalapril dose appeared to relax vasomotor tone more than the low dose. However, concentrating on vasomotor tone is not sufficient in severe heart failure. Recent studies on flosequinan and prostacyclin, although producing vasodilation, failed to cause clinical benefit' 1213 '. When planning the study, the neurohumoral concept of heart failure progression and its impact on mortality was established and activation of vasoconstrictor systems became known to be a major determinant of the clinical efficacy of treatment with angiotensin converting enzyme inhibitors' 1415 '.
The actions of angiotensin converting enzyme inhibitors differ from those of other vasodilators in heart failure as they include various beneficial effects on endogenous neurohumoral systems. Aside from interfering with the activity of the renin system the sympathetic nervous system is also impaired, particularly if a high sympathetic tone prevails' 16171 . With angiotensin converting enzyme inhibitor treatment, vasodilating prostaglandins may be released'
181
. This may be important therapeutically as the haemodynamic effects of angiotensin converting enzyme inhibition may be blunted by inhibitors of prostaglandin synthesis' 191 . Looking, in retrospect, at a small subgroup of patients taking a 100 mg dose of aspirin in this study, however, patients on concomitant aspirin had a similar outcome as those without aspirin.
To investigate a possible dose relationship of enalapril with regard to neurohumoral activation, we measured plasma levels of aldosterone to estimate angiotensin-mediated aldosterone production, noradrenaline reflecting peripheral sympathetic nervous activity and atrial natriuretic peptide release. We further determined big endothelin, the precursor of the endothelial hormone endothelin-1. Although big endothelin is not the physiological effector molecule, it constitutes the major part of immunoreactive endothelin in severe heart failure and has been shown to be a powerful prognostic marker 110 ' 201 . However, the higher enalapril dose did not affect the circulating amounts of any neurohumoral variable significantly more than the low dose. In our previous study with captopril a high captopril dose decreased aldosterone and atrial natriuretic peptide plasma levels, while a low captopril dose did not affect these variables'
91
. However, the two angiotensin converting enzyme inhibitor dosages in each study (an average dose of 30 mg and 100 mg captopril versus a standardized dose of 10 mg and 40 mg enalapril), are not bioequivalent. Therefore, it is not surprising that the magnitude of effect of the two captopril dosages differed from that observed with the two enalapril dosages.
Nevertheless, one could speculate from the tendency of plasma norepinephrine to increase more in our study after 1 year's treatment with low dose enalapril than with a high dose, that in severe heart failure a vigorous angiotensin converting enzyme inhibitor dose is warranted to blunt or delay the deleterious increase in sympathetic stimulation' 2 ' 1 .
Effects on kidney function
Serum creatinine levels did not reveal any different effect of the high enalapril dose compared to the low dose on the kidney despite a considerable drop in blood pressure with the high dose. Of importance, no patients had to be prematurely withdrawn from double-blind treatment because of deterioration in renal function in either group. In theory, a small rise in serum creatinine as a result of angiotensin converting enzyme inhibition might reflect a beneficial change in glomerular haemodynamics'
221
. It may also be important to consider that intense angiotensin converting enzyme inhibition during long-term treatment with angiotensin converting enzyme inhibitors may enhance a furosemide induced diuresis'
231
. This could also have contributed to the greater clinical improvement in the high-dose group in terms of a more pronounced alleviation of heart failure symptoms through a more effective action of concomitant diuretic treatment.
Conclusions
In this study on severe heart failure patients, only improvement in New York Heart Association stage and reduction in diastolic blood pressure were dose related, with patients treated with 40 mg enalapril having a more pronounced effect than those who continued with 10 mg enalapril. Conversely, single invasive haemodynamic and maximum exercise variables appeared not to be dose related beyond a dose range of 10 mg enalapril, since relative differences in change from baseline between the low-dose reference group (no further enhancement in enalapril) and the high-dose group (titration increased from 10 to 40 mg enalapril) were not significantly different. It is possible that the high-dose related improvement in functional capacity was the result of mechanisms that are distinct from those which usually cause an improvement in single haemodynamic variables at rest or enable the patients to enhance their ability to exercise. Also, functional capacity which results from the perception of symptoms may exhibit a different sensitivity to angiotensin converting enzyme inhibition over time.
In summary, the results of this investigation support the hypothesis that high-dose angiotensin converting enzyme inhibitor treatment may be more efficacious than a low dose concerning symptoms accompanying an advanced heart failure state. Both dosages were generally well tolerated and equally safe with respect to kidney function. Notably, dose dependence may not be the same for all variables reasonably assessed in a cohort of severe heart failure patients. Thus, dose-effect considerations appear essential to gain the maximum benefit from angiotensin converting enzyme inhibitors and several large scale trials (ATLAS, NETWORK, ACHIEVE) are currently underway to investigate this important issue. The results of this study strongly suggest that dose-effect considerations should not be confined to patients with mild to moderate heart failure but should be extended to the advanced stage of the disease.
